Lonza Group AG, together with its subsidiaries, operates as a contract development and manufacturing organization for pharma and biotech companies in Europe, North and Central America, Latin America, Asia.MoreShow less
Profile & Fundamentals
Lonza Group: Company identity, ownership, reported financial performance, balance sheets, and corporate actions.
Profile & Fundamentals
Lonza Group Profile & Fundamentals
Examine company identity, ownership, reported performance, valuation, balance-sheet resilience, dividends, buybacks, and material corporate events.
Explore this pageJump to a Profile & Fundamentals section
Explore this research
Profile & Fundamentals contents
Jump directly to any section
Company and Market Context
Company Profile & Ownership
Lonza Group AG, together with its subsidiaries, operates as a contract development and manufacturing organization for pharma and biotech companies in Europe, North and Central America, Latin America, Asia, Australia, New Zealand, and internationally. It operates through Integrated Biologics; Advanced Synthesis; and Specialized Modalities segments. The Integrated Biologics segment offers CDMO biologics services from clinical development, drug substance, and drug product manufacturing; and operates mammalian and drug product platforms. Its Advanced Synthesis segment manufactures antibody-drug conjugates (ADCs) and other bioconjugates, small molecules, and highly potent active pharmaceutical ingredients; and operates small molecules and bioconjugates platforms. The Specialized Modalities segment operates various technologies, such as spanning cell & gene, microbial, bioscience, and mRNA. Lonza Group AG was incorporated in 1897 and is headquartered in Basel, Switzerland.
Company profile record
Lonza Group AG
Common Stock · Health Care · Biotechnology
Company
- Company / asset
- Lonza Group AG
- Security type
- Common Stock
- Sector
- Health Care
- Industry
- Biotechnology
- HQ
- 🇨🇭 Switzerland
- Head office
- Muenchensteinerstrasse 38, Basel, Switzerland, 4002
Leadership & scale
- Chief executive
- Dr. Wolfgang Wienand Ph.D.
- CEO year born
- 1972
- Full-time employees
- 20.1K
- Fiscal year end
- December
Fundamentals snapshot
- Market Cap
- CHF 40.3B
- P/E
- 64.7x
- Revenue (Q2 26)
- CHF 3.4B
- Profit (Q2 26)
- CHF 591.0M
- Dividend Yield
- 0.8%
- Revenue (FY 25)
- CHF 6.5B
- Shares in public float
- 69.7M
- Insider ownership
- 0.09%
Reporting & identifiers
- Symbol
- LONN.SIX
- Listing
- 🇨🇭 Switzerland | Dividend Tax: 35%
- Ticker Currency
- CHF
- Income Statement Currency
- CHF
- Balance Sheet Currency
- CHF
- Cash Flow Currency
- CHF
- EPS Currency
- CHF
- Contract Type
- SPOT
- ISIN
- CH0013841017
- Asset ID
- equity_84fa1055-5544-5b95-ab2c-1dcbae92f9ab
Ownership
Shares Outstanding
Latest: 69.9M | Max: 74.8M | Min: 68.5M
Latest reported ownership snapshot
As of Oct 1, 2026Float Shares
99.72%
69.7M latest reported shares
Insider Ownership
0.09%
Latest reported insider stake
Short Float
--
Latest reported short interest / float
Source tablesView ownership tables
Shares Outstanding
Annual reported shares outstanding; up to 10 reporting dates.
Scroll the table to see every column.
| Reporting date | Shares outstanding |
|---|---|
| 2017-01-01 | 68,460,200 |
| 2018-01-01 | 74,614,700 |
| 2019-01-01 | 74,597,200 |
| 2020-01-01 | 74,811,800 |
| 2021-01-01 | 74,484,900 |
| 2022-01-01 | 74,306,200 |
| 2023-01-01 | 72,700,700 |
| 2024-01-01 | 74,119,700 |
| 2025-01-01 | 70,181,200 |
| 2026-01-01 | 69,940,800 |
Top Holders
Available reported ownership records.
No reported records are available in this preview.
Earnings, Profitability & Valuation
Earnings, Profitability & Valuation
Earnings & Revenue
Earnings and Revenue Trajectory
AI Review
Headline financial results presented a confusing picture that masked robust underlying manufacturing health. In fiscal 2025, the company posted an optical statutory net loss of 275 million Swiss francs despite full-year sales jumping 19.2% to 6.53 billion francs. Forensic inspection confirms this paper loss stemmed from non-cash accounting write-downs taken to prepare the consumer capsules business for sale, rather than operational decay. Underlying contract manufacturing is gathering powerful momentum. Continuing operations accelerated into the first half of 2026, delivering 3.37 billion francs in revenue and a 38.7% surge in net profit to 591 million francs. As one-off separation noise fades, high-margin commercial biologics are establishing a strong, recurring earnings foundation.
Headline financial results presented a confusing picture that masked robust underlying manufacturing health. In fiscal 2025, the company posted an optical statutory net loss of 275 million Swiss francs despite full-year sales jumping 19.2% to 6.53 billion francs. Forensic inspection confirms this paper loss stemmed from non-cash accounting write-downs taken to prepare the consumer capsules business for sale, rather than operational decay. Underlying contract manufacturing is gathering powerful momentum. Continuing operations accelerated into the first half of 2026, delivering 3.37 billion francs in revenue and a 38.7% surge in net profit to 591 million francs. As one-off separation noise fades, high-margin commercial biologics are establishing a strong, recurring earnings foundation.
Revenue, Net Income, and Free Cash Flow
Latest: CHF 6.5B | Max: CHF 6.7B | Min: CHF -852.0M
Valuation
P/E Ratio (TTM)iPublished valuation snapshots use the earnings basis recorded with each observation. Source tables retain that basis.
Latest: >100x
Profitability & Margins
Margins and Operating Efficiency
AI Review
Profitability is experiencing structural expansion as customer demand shifts heavily toward high-complexity biologic medicines. Operating margins rebounded to 21.2% in 2025, while continuing operations achieved core margins of 34.8% during the first half of 2026. This operational strength reflects fixed-cost dilution across expanding production suites and commanding pricing power in specialized antibody-drug conjugates. While standard factory maintenance will produce normal second-half seasonal moderation, structural margins remain firmly elevated. Jettisoning lower-margin consumer capsule products and filling large-scale bioreactors with proprietary client therapies establishes a durable operating margin floor above 33% over the multi-year planning horizon.
Profitability is experiencing structural expansion as customer demand shifts heavily toward high-complexity biologic medicines. Operating margins rebounded to 21.2% in 2025, while continuing operations achieved core margins of 34.8% during the first half of 2026. This operational strength reflects fixed-cost dilution across expanding production suites and commanding pricing power in specialized antibody-drug conjugates. While standard factory maintenance will produce normal second-half seasonal moderation, structural margins remain firmly elevated. Jettisoning lower-margin consumer capsule products and filling large-scale bioreactors with proprietary client therapies establishes a durable operating margin floor above 33% over the multi-year planning horizon.
Profitability Margins
Latest: 35.2% | Max: 54.4% | Min: -4.2%
Latest Profitability Ratios as of 2025-12-31
Gross Margin
35.2%
Gross profit / revenue
Operating Margin
21.2%
Operating income / revenue
Net Margin
-4.2%
Net income / revenue
FCF Margin
-3.1%
Free cash flow / revenue
Source tablesView earnings, profitability & valuation tables
Revenue, Net Income, and Free Cash Flow
Annual reported results, using the source statement's recorded USD conversion. Up to 10 reporting periods; missing values are not estimated.
Scroll the table to see every column.
| Period end | Revenue (USD) | Net income (USD) | Free cash flow (USD) |
|---|---|---|---|
| 2016-12-31 | 4,050,980,392.16 | 295,098,039.22 | 389,215,686.27 |
| 2017-12-31 | 4,669,404,517.45 | 725,872,689.94 | 432,238,193.02 |
| 2018-12-31 | 5,643,584,521.38 | 569,246,435.85 | 564,154,786.15 |
| 2019-12-31 | 4,346,074,380.17 | 780,991,735.54 | 184,917,355.37 |
| 2020-12-31 | 5,093,785,310.73 | 981,920,903.95 | 177,401,129.94 |
| 2021-12-31 | 5,930,921,052.63 | 3,228,070,175.44 | -135,964,912.28 |
| 2022-12-31 | 6,727,567,567.57 | 1,313,513,513.51 | -921,081,081.08 |
| 2023-12-31 | 7,977,434,679.33 | 776,722,090.26 | -312,351,543.94 |
| 2024-12-31 | 6,041,896,361.63 | 701,212,789.42 | -157,662,624.04 |
| 2025-12-31 | 8,235,813,366.96 | -346,784,363.18 | -257,250,945.78 |
Published P/E Ratio
Published valuation snapshots retain each observation's earnings basis.
Scroll the table to see every column.
| Period end | P/E (times earnings) | Earnings basis |
|---|---|---|
| 2025-12-31 | 104.55 | Trailing four quarters |
| 2024-12-31 | 30.79 | Trailing four quarters |
| 2023-12-31 | 12.17 | Trailing four quarters |
| 2022-12-31 | 27.71 | Annual net income |
| 2021-12-31 | 19.27 | Annual net income |
Profitability Margins
Matching annual reporting dates. Values are percentages.
Scroll the table to see every column.
| Period end | Gross margin (%) | Operating margin (%) | Net margin (%) | Free cash flow margin (%) |
|---|---|---|---|---|
| 2016-12-31 | 34.56 | 13.21 | 7.28 | 9.61 |
| 2017-12-31 | 35.82 | 15.13 | 15.55 | 9.26 |
| 2018-12-31 | 36.41 | 17.07 | 10.09 | 10 |
| 2019-12-31 | 38.53 | 20.13 | 17.97 | 4.25 |
| 2020-12-31 | 37.84 | 20.79 | 19.28 | 3.48 |
| 2021-12-31 | 36.4 | 15.14 | 54.43 | -2.29 |
| 2022-12-31 | 36.96 | 21.68 | 19.52 | -13.69 |
| 2023-12-31 | 27.04 | 12.71 | 9.74 | -3.92 |
| 2024-12-31 | 35.99 | 19.93 | 11.61 | -2.61 |
| 2025-12-31 | 35.25 | 21.16 | -4.21 | -3.12 |
Public data excerpt created by iPulse AI and published by Future Edge Group FZE. Source: eodhd. Snapshot retrieved 2026-09-15.
Use is subject to the iPulse AI Terms of Service and applicable source rights. Missing inputs are not estimated. Full access includes the remaining records, research and interactive tools.
Complete Research Workspace
Unlock the complete Profile & Fundamentals
Sign in to verify your access, or upgrade to the Base plan to open the complete profile & fundamentals and available source data.